COMPANY INSIGHT

Sponsored by Dr. Paul Lohmann

Your competent Partner for high value Mineral Salts

More than 135 years of experience in the development and production of Mineral Salts have strengthened our excellent know-how and made Dr. Paul Lohmann® one of the world’s leading manufacturers of high-quality Mineral Salts. GMP-certified production facilities in Germany and standardized manufacturing processes ensure high batch-to-batch consistency and traceability. Our multiple production capabilities and innovative thinking enable us to modify specific chemical and physical parameters to meet our customers' requirements.

From customized dry Mineral Salts and Salt blends to tailor-made Salt solutions and regulatory support - our customer-centric approach makes Dr. Paul Lohmann® your reliable supplier for Mineral Salts used as APIs (Active Pharmaceutical Ingredients), as excipients in pharmaceutical applications or as process aids in biotechnological production.

Salts of Amino Acids 

Amino Acids are very often used as nutrients in cell culture media and are therefore an indispensable part of many upstream processes. However, many Amino Acids are poorly or not soluble in an aqueous medium, which can lead to losses in yield and poor quality of the finished products.

To counteract these solubility problems, Paul Lohmann® developed Tyrosine and Aspartic Acid Salts with improved solubility profiles and increased dissolution rates.

  • L-Tyrosine Disodium Salt
  • L-Aspartic Acid Sodium Salt

Free-flowing Salts 

Dipotassium Hydrogen Phosphate 3-hydrate, Ammonium Sulfate, Sodium Sulfate 10-hydrate and Magnesium Acetate are widely used in biopharmaceutical and diagnostic applications. It is known that these products have a high tendency to lump due to their high hygroscopicity, which hinders and complicates the entire production process. Dr. Paul Lohmann® developed free-flowing qualities that ultimately reduce the manufacturer‘s time and costs.

  • Ammonium Sulfate
  • Magnesium Acetate
  • Dipotassium Hydrogen Phosphate 3-hydrate
  • Sodium Sulfate 10-hydrate

Low in Endotoxins  

Endotoxins can cause undesirable effects on cell proliferation or cell function. Low in Endotoxin qualities enable the development of high sensitive cell lines in an optimal and controlled environment.

Sodium Succinate 6-hydrate is used as buffer in cell culture media and as excipient. Dr. Paul Lohmann® has invested into a state-of-the-art dedicated GMP plant for Low in Endotoxin Salts. With our unique Quality by Design approach, we have developed Sodium Succinate 6-hydrate Low in Endotoxins. The advantage for the customer lies in the seamless integration and reduced risks and costs in production.

In addition to Sodium Succinate 6-hydrate, Dr. Paul Lohmann® offers a wide range of Low in Endotoxin Salts such as Acetates, Sulfates, Citrates and Phosphates.

MORE INFOMATION

Phosphates  

Dr. Paul Lohmann® manufactures a broad portfolio of high-quality Phosphates adaptable to your specific needs. Phosphates are required in all biopharmaceutical production streams. While our Phosphates meet the requirements of common pharmacopoeias, we also offer individual analytical profiles. These as well as Phosphate blends and a variety of individual packaging make Dr. Paul Lohmann® your solution-oriented supplier.

Our range of Phosphates:

Potassium

Monopotassium Phosphate | Dipotassium Hydrogen Phosphate | Dipotassium Hydrogen Phosphate 3-hydrate

Sodium

Monosodium Phosphate, anhydrous | Monosodium Phosphate 1-hydrate | Monosodium Phosphate 2-hydrate | Disodium Hydrogen Phosphate, anhydrous | Disodium Hydrogen Phosphate 2-hydrate | Disodium Hydrogen Phosphate 7-hydrate | Disodium Hydrogen Phosphate 12-hydrate | Trisodium Phosphate 12-hydrate

Contact information

Dr. Paul Lohmann GmbH & Co. KGaA

Hauptstrasse 2

31860 Emmerthal/Germany

T +49 5155 63-0

Email: sales@lohmann4minerals.com

www.lohmann4minerals.com

Go to top

02/24/2024 03:29:04
  • Home | Improving safety for multiple drug regimes 
  • In this issue
  • Contents
  • Curtis Health Caps
  • Astrix
  • Briefing
  • Industry news
  • The pharma industry briefing
  • Covid-19 executive briefing by GlobalData
  • Owen Mumford Company Insight
  • Owen Mumford
  • Comment
  • Use of AI in the fight against Covid-19 shows mixed results
  • What does Ireland’s tax hike mean for pharma?
  • Chinese review designations lag behind US and EU
  • The business benefits of text mining in life sciences
  • Mettler Toledo
  • HOF Sonderanlagenbau
  • In Depth
  • Narrow FDA panel vote on Merck’s molnupiravir bolsters outlook on mAbs
  • The challenges of multiple drugs safety reporting
  • 3D printing in drug manufacturing: unlocking future possibilities
  • Can drug repurposing uncover better treatments for UTIs?
  • Pfizer and Takeda deals put a spotlight on value-based pricing
  • Lethal injection: can pharma kill the death penalty?
  • Mimotopes Company Insight
  • Mimotopes
  • In Data
  • Middle-income countries’ healthcare sectors to keep rising through to 2024
  • Data analytics hiring levels in clinical trial operations rose in October
  • Industrial automation innovation in pharma rebounded in the last quarter
  • Global markets and indices
  • Macro-economic indicators
  • Macro-economic indicators (page 2)
  • Yearbook
  • SHL Medical
  • Dr. Paul Lohmann Company Insight
  • Dr. Paul Lohmann
  • Novo Nordisk
  • Nipro
  • Events
  • Next issue
12/15/2021 00:00:00